Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.46 |
| ▸ | NPY1R | P25929 | 11/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.46 |
| ▸ | NPY2R | P49146 | 7/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184455 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL15826828 | 0.88 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL14773211 | 0.87 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL12892412 | 0.87 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL12892411 | 0.87 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL12892406 | 0.87 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL31072586 | 0.87 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31181284 | 0.86 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL31072445 | 0.85 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL30472837 | 0.85 | NOD1 (0.50) | NPY4RNPY1RNPY5RNPY2RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | NPY4R 86/4885NPY1R 214/4885NPY5R 639/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | NPY4R 178/4885NPY1R 497/4885NPY5R 501/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | NPY4R 32/4885NPY1R 74/4885NPY5R 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.